Back to top
more

Regeneron Pharmaceuticals (REGN)

(Real Time Quote from BATS)

$883.59 USD

883.59
322,039

-7.09 (-0.80%)

Updated Apr 26, 2024 03:39 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for REGN

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

Fiscal Year End for Regeneron Pharmaceuticals, Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 10,845 7,742 5,695 3,587 3,214
Receivables 5,667 5,329 6,037 4,115 2,672
Notes Receivable 0 0 0 0 0
Inventories 2,581 2,402 1,951 1,917 1,416
Other Current Assets 387 411 332 161 387
Total Current Assets 19,479 15,884 14,015 9,779 7,689
Net Property & Equipment 4,146 3,763 3,482 3,222 2,890
Investments & Advances 5,397 6,592 6,838 3,136 3,257
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 2,575 1,724 877 859 824
Intangibles 1,039 916 0 0 0
Deposits & Other Assets 444 336 223 168 145
Total Assets 33,080 29,215 25,435 17,163 14,805
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 607 589 564 476 418
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 720 0 0
Accrued Expenses 0 0 0 0 0
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 2,817 2,552 2,649 2,222 1,679
Total Current Liabilities 3,423 3,141 3,933 2,697 2,097
Mortgages 0 0 0 0 0
Deferred Taxes/Income 127 70 73 58 619
Convertible Debt 0 0 0 0 0
Long-Term Debt 1,983 1,981 1,980 1,979 0
Non-Current Capital Leases 720 720 0 717 714
Other Non-Current Liabilities 854 638 680 687 286
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 7,107 6,551 6,666 6,138 3,716
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 11,354 9,949 8,088 6,716 4,429
Retained Earnings 27,260 23,307 18,968 10,893 7,380
Other Equity -81 -239 -26 29 21
Treasury Stock 12,560 10,353 8,261 6,613 740
Total Shareholder's Equity 25,973 22,664 18,769 11,025 11,090
Total Liabilities & Shareholder's Equity 33,080 29,215 25,435 17,163 14,805
Total Common Equity 25,973 22,664 18,769 11,025 11,090
Shares Outstanding 109.70 109.30 108.50 107.10 110.20
Book Value Per Share 236.76 207.36 172.98 102.94 100.63

Fiscal Year End for Regeneron Pharmaceuticals, Inc falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 10,845 9,914 8,928 8,960
Receivables NA 5,667 5,585 5,121 5,119
Notes Receivable NA 0 0 0 0
Inventories NA 2,581 2,562 2,508 2,425
Other Current Assets NA 387 575 366 406
Total Current Assets NA 19,479 18,635 16,923 16,909
Net Property & Equipment NA 4,146 4,006 3,923 3,881
Investments & Advances NA 5,397 5,779 6,327 6,067
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 2,575 2,317 2,139 1,925
Intangibles NA 1,039 1,017 953 929
Deposits & Other Assets NA 444 410 393 350
Total Assets NA 33,080 32,163 30,658 30,060
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 607 537 547 600
Current Portion Long-Term Debt NA 0 0 0 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 0 0 0 0
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 2,817 3,062 2,557 2,501
Total Current Liabilities NA 3,423 3,599 3,104 3,100
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 127 125 116 86
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 1,983 1,983 1,982 1,982
Non-Current Capital Leases NA 720 720 720 720
Other Non-Current Liabilities NA 832 717 677
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 7,107 7,259 6,640 6,565
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 0 0 0 0
Capital Surplus NA 11,354 11,252 10,889 10,598
Retained Earnings NA 27,260 26,101 25,093 24,125
Other Equity NA -81 -177 -198 -182
Treasury Stock NA 12,560 12,271 11,766 11,046
Total Shareholder's Equity NA 25,973 24,904 24,018 23,495
Total Liabilities & Shareholder's Equity NA 33,080 32,163 30,658 30,060
Total Common Equity 0 25,973 24,904 24,018 23,495
Shares Outstanding 109.70 109.70 108.90 108.50 109.70
Book Value Per Share 0.00 236.76 228.69 221.36 214.18